Psoriasis - KOL Insight

How do KOLs expect the future availability of biosimilar ustekinumab to impact the first-line biologic market? What clinical benefits are exciting experts about BMS' Tyk2 inhibitor Sotyktu and where do they see it delivering value? KOLs critically assess the prospects of launched and pipeline therapies.

In addition to the full report, licensed users have access to the following KOL Bulletins via the Attachments area.

Table of Contents

Executive summary (7)

Research Objectives (5)

Anti-TNF drugs (16)

• Humira (adalimumab; AbbVie) (9)
  • Key insights summary (9)
• Cimzia (certolizumab pegol; UCB) (7)
  • Key insights summary (7)

Anti-IL17 drugs (46)

• Cosentyx (secukinumab; Novartis) (13)
  • Key insights summary (13)
• Taltz (ixekizumab; Lilly) (10)
  • Key insights summary (10)
• Siliq (US)/Kyntheum (EU) (brodalumab; Ortho Dermatologics/LEO Pharma) (8)
  • Key insights summary (8)
• Bimzelx (bimekizumab; UCB) (15)
  • Key insights summary (15)

Anti-IL-12/23 drugs (12)

• Stelara (ustekinumab; Janssen Biotech) (12)
  • Key insights summary (12)

Anti-IL-23 drugs (39)

• Tremfya (guselkumab; Janssen Biotech) (16)
  • Key insights summary (16)
• Ilumya/Ilumetri (tildrakizumab; Sun Pharma/Almirall) (13)
  • Key insights summary (13)
• Skyrizi (risankizumab; AbbVie) (10)
  • Key insights summary (10)

PDE IV antagonists (15)

• Otezla (apremilast; Amgen) (15)
  • Key insights summary (15)

Tyrosine Kinase 2 inhibitor (21)

• Sotyktu (deucravacitinib; Bristol Myers Squibb) (21)
  • Key insights summary (21)

Topical formulations (11)

• Zoryve (roflumilast; Arcutis Biotherapeutics) and Vtama (tapinarof; Dermavant Sciences) (11)
  • Key insights summary (11)

Pipeline drugs (8)

• Piclidenoson (Can-Fite BioPharma) (8)
  • Key insights summary (8)

Future dynamics of existing treatments for psoriasis (8)

• Key insights summary (8)
  • Usage of anti-TNFs is mostly stable, with a declining trend in the US but an increasing trend in Europe (6)

Future outlook and evolution of the psoriasis market (8)

• Key insights summary (8)
  • Interleukin therapy, deucravacitinib and biosimilar ustekinumab will be used earlier in the treatment paradigm (6)

Appendix (4)

• KOL Details (4)